BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S. Long term omeprazole therapy for reflux esophagitis: Follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J Gastroenterol 2000; 6(6): 789-792 [PMID: 11819697 DOI: 10.3748/wjg.v6.i6.789]
URL: https://www.wjgnet.com/1007-9327/full/v6/i6/789.htm
Number Citing Articles
1
Yvan Vandenplas, Hegar Badriul, Sylvia Salvatore, Bruno Hauser. Pharmacotherapy of gastro-oesophageal reflux disease in children: focus on safetyExpert Opinion on Drug Safety 2002; 1(4): 355 doi: 10.1517/14740338.1.4.355
2
Yvan Vandenplas, Silvia Salvatore, Bruno Hauser. The Gastroesophageal Reflux in Infants and Children2004; : 147 doi: 10.1007/978-3-642-18906-7_19
3
M.E. Numans. Vademecum permanente nascholing huisartsen2006; : 1635 doi: 10.1007/978-90-313-8808-0_863
4
Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions2006; : 2615 doi: 10.1016/B0-44-451005-2/00597-0
5
Adriana Sánchez-García, Mario Simental-Mendía, Luis E. Simental-Mendía. Effect of Proton-Pump Inhibitors on Glucose and Insulin Metabolism on Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsCurrent Pharmaceutical Design 2020; 26(32): 4007 doi: 10.2174/1381612826666200523170718
6
Javier P. Gisbert, Josep M. Piqué. Indicaciones y consecuencias de la erradicación de Helicobacter pylori en la enfermedad por reflujo gastroesofágicoMedicina Clínica 2005; 124(18): 697 doi: 10.1157/13075094
7
Gerardo M. Castillo, Akiko Nishimoto-Ashfield, Aryamitra A. Banerjee, Jennifer A. Landolfi, Alexander V. Lyubimov, Elijah M. Bolotin. Omeprazole and PGC-Formulated Heparin Binding Epidermal Growth Factor Normalizes Fasting Blood Glucose and Suppresses Insulitis in Multiple Low Dose Streptozotocin Diabetes ModelPharmaceutical Research 2013; 30(11): 2843 doi: 10.1007/s11095-013-1112-6
8
B. DELANEY, K. McCOLL. Review article: Helicobacter pylori and gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics 2005; 22(s1): 32 doi: 10.1111/j.1365-2036.2005.02607.x
9
V. Tolia, K. Boyer. Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of SafetyDigestive Diseases and Sciences 2008; 53(2): 385 doi: 10.1007/s10620-007-9880-7
10
Huiqin Gao, Lunan Li, Ke Geng, Changzheng Teng, Yuanyuan Chen, Fei Chu, Yi Zhao. Use of proton pump inhibitors for the risk of gastric cancerMedicine 2022; 101(49): e32228 doi: 10.1097/MD.0000000000032228
11
Hyun Jin Song, Nakyung Jeon, Patrick Squires. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysisEuropean Journal of Clinical Pharmacology 2020; 76(10): 1437 doi: 10.1007/s00228-020-02927-8
12
Choo Hean Poh, Tomás Navarro-Rodriguez, Ronnie Fass. Review: Treatment of Gastroesophageal Reflux Disease in the ElderlyThe American Journal of Medicine 2010; 123(6): 496 doi: 10.1016/j.amjmed.2009.07.036
13
C. Knippig, P. Malfertheiner. Gastroesophageal Reflux Disease2006; : 73 doi: 10.1007/3-211-32317-1_6
14
Michael D Burkitt, Andrea Varro, D Mark Pritchard. Importance of gastrin in the pathogenesis and treatment of gastric tumorsWorld Journal of Gastroenterology 2009; 15(1): 1-16 doi: 10.3748/wjg.15.1
15
Heloisa B. Assalin, Kelly Cristiane Gabriel De Almeida, Dioze Guadagnini, Andrey Santos, Caio J. Teixeira, Silvana Bordin, Guilherme Z. Rocha, Mario J. A. Saad. Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse LiverInternational Journal of Molecular Sciences 2022; 23(22): 13766 doi: 10.3390/ijms232213766
16
A.G. Neto, R.A. Hickman, A. Khan, C. Nossa, Z. Pei. The Microbiota in Gastrointestinal Pathophysiology2017; : 1 doi: 10.1016/B978-0-12-804024-9.00001-X
17
Kohzo Takebayashi, Shintaro Sakurai, Tatsuhiko Suzuki, Kenichiro Hori, Tomoko Terasawa, Rika Naruse, Kenji Hara, Mariko Suetsugu, Takafumi Tsuchiya, Hiromi Aoki, Takashi Hamasaki, Hiroshi Shuutou, Toshihiko Inukai. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetesEndocrine Journal 2014; 61(10): 1031 doi: 10.1507/endocrj.EJ14-0208
18
Meyler's Side Effects of Drugs2016; : 334 doi: 10.1016/B978-0-444-53717-1.01181-1
19
Takahisa Furuta, Naohito Shirai, Mitsushige Sugimoto, Kyoichi Ohashi, Takashi Ishizaki. Pharmacogenomics of proton pump inhibitorsPharmacogenomics 2004; 5(2): 181 doi: 10.1517/phgs.5.2.181.27483
20
Robert T. Jensen. Consequences of Long‐Term Proton Pump Blockade: Insights from Studies of Patients with GastrinomasBasic & Clinical Pharmacology & Toxicology 2006; 98(1): 4 doi: 10.1111/j.1742-7843.2006.pto_378.x
21
H.J. De Silva. Side Effects of Drugs Annual 2002; 25: 416 doi: 10.1016/S0378-6080(02)80043-5
22
Xiao Bai, Si-Qi Ding, Xue-Ping Zhang, Ming-Hao Han, Dong-Qiu Dai. Exposure to Commonly Used Drugs and the Risk of Gastric Cancer: An Umbrella Review of Meta-AnalysesCancers 2023; 15(2): 372 doi: 10.3390/cancers15020372
23
Carol Chiung-Hui Peng, Yu-Kang Tu, Gin Yi Lee, Rachel Huai-En Chang, Yuting Huang, Khulood Bukhari, Yao-Chou Tsai, Yunting Fu, Huei-Kai Huang, Kashif M Munir. Effects of Proton Pump Inhibitors on Glycemic Control and Incident Diabetes: A Systematic Review and Meta-analysisThe Journal of Clinical Endocrinology & Metabolism 2021; 106(11): 3354 doi: 10.1210/clinem/dgab353
24
Takahisa Furuta, Naohito Shirai, Mitsushige Sugimoto, Akiko Nakamura, Akira Hishida, Takashi Ishizaki. Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based TherapiesDrug Metabolism and Pharmacokinetics 2005; 20(3): 153 doi: 10.2133/dmpk.20.153
25
A. S. RAGHUNATH, C. O'MORAIN, R. C. MCLOUGHLIN. Review article: the long‐term use of proton‐pump inhibitorsAlimentary Pharmacology & Therapeutics 2005; 22(s1): 55 doi: 10.1111/j.1365-2036.2005.02611.x
26
Kwong Ming Fock, Choo Hean Poh. Gastroesophageal reflux diseaseJournal of Gastroenterology 2010; 45(8): 808 doi: 10.1007/s00535-010-0274-9
27
James Reynolds. Practical Gastroenterology and Hepatology Board Review Toolkit2016; : 181 doi: 10.1002/9781119127437.ch28